Last Posted: Oct 26, 2018
- High price of precision medicine forces cancer patients to make agonizing choices
L Szabo, USA Today, October 26, 2018 - Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan.
Graham Jonathan et al. Journal of managed care & specialty pharmacy 2018 Jun 24(6) 544-553 - ETHICS EVALUATION REVEALING DECISION-MAKER MOTIVES: A CASE OF NEONATAL SCREENING.
Raimond Véronique et al. International journal of technology assessment in health care 2018 Jan 34(2) 189-195 - Genetic Information Nondiscrimination Act and the Affordable Care Act: When Two Is Better Than One.
Rich Kelly et al. Genetic testing and molecular biomarkers 2018 Jun 22(6) 331-332 - A comparison of family financial and employment impacts of fragile X syndrome, autism spectrum disorders, and intellectual disability.
Ouyang Lijing et al. Research in developmental disabilities 2014 Jul 35(7) 1518-27 - A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola.
McGann Patrick T et al. The Journal of pediatrics 2015 Dec 167(6) 1314-9 - Accounting for differences in healthcare utilization and expenditures among US males with haemophilia by type of health insurance.
Guh S et al. Haemophilia : the official journal of the World Federation of Hemophilia 2017 23(2) e147-e151 - CDC Grand Rounds: Newborn screening and improved outcomes.
et al. MMWR. Morbidity and mortality weekly report 2012 Jun 61(21) 390-3 - Emergency Department Visits and Inpatient Admissions Associated with Priapism among Males with Sickle Cell Disease in the United States, 2006-2010.
Dupervil Brandi et al. PloS one 2016 11(4) e0153257 - Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.
Grosse Scott D et al. Expert review of pharmacoeconomics & outcomes research 2015 Apr 15(2) 267-83
No hay comentarios:
Publicar un comentario